Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Lung Cancer
- Interventions
- Biological: bevacizumabBiological: TecemotideDrug: carboplatinDrug: cyclophosphamideDrug: paclitaxelRadiation: radiotherapy
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 70
- Registration Number
- NCT00828009
- Locations
- 🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸Hematology Oncology Associates - Skokie, Skokie, Illinois, United States
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00821886
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 30
- Registration Number
- NCT00820872
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸Kalispell Regional Medical Center, Kalispell, Montana, United States
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
- Conditions
- CarcinosarcomaMesenchymal TumorLeiomyosarcoma
- Interventions
- First Posted Date
- 2008-12-31
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 41
- Registration Number
- NCT00815945
- Locations
- 🇩🇪
Malteser Krankenhaus, Gynäkologie und Geburtshilfe, Bonn, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany
🇩🇪Evangelisches Krankenhaus Düsseldorf, Frauenklinik, Duesseldorf, Germany
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: RG1507Drug: RO1507Drug: erlotinib [Tarceva]Drug: bevacizumab [Avastin]Drug: pemetrexelDrug: carboplatinDrug: capecitabine [Xeloda]Drug: sorafenibDrug: temozolomideDrug: cetuximabDrug: paclitaxelDrug: etoposideDrug: mFOLFOX6Drug: trastuzumab [Herceptin]Drug: docetaxelDrug: gemcitabineDrug: irinotecan
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00811993
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
- Conditions
- Cervical CancerPrecancerous Condition
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT00811408
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Biological: RituximabDrug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: PrednisoneDrug: IfosfamideDrug: CarboplatinDrug: EtoposideDrug: High-dose cyclophosphamideProcedure: PET scan
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 27
- Registration Number
- NCT00809341
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT00809133
- Locations
- 🇬🇧
1200.12.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1200.12.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
- Conditions
- Stage I Uterine Corpus Cancer AJCC v7Endometrial Clear Cell AdenocarcinomaNeurotoxicity SyndromeStage II Uterine Corpus Cancer AJCC v7Endometrial Serous AdenocarcinomaFatigueObesity
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyDrug: CarboplatinRadiation: Internal Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyOther: Laboratory Biomarker AnalysisDrug: PaclitaxelOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 601
- Registration Number
- NCT00807768
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
- Conditions
- Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 5
- Registration Number
- NCT00807755
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.